448 related articles for article (PubMed ID: 21948233)
21. Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC.
Dai Y; Wei Q; Schwager C; Hanne J; Zhou C; Herfarth K; Rieken S; Lipson KE; Debus J; Abdollahi A
Radiat Oncol; 2018 Jan; 13(1):1. PubMed ID: 29304828
[TBL] [Abstract][Full Text] [Related]
22. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
Zdzalik D; Dymek B; Grygielewicz P; Gunerka P; Bujak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K
J Cancer Res Clin Oncol; 2014 Apr; 140(4):589-98. PubMed ID: 24509625
[TBL] [Abstract][Full Text] [Related]
23. Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.
Perez CA; Velez M; Raez LE; Santos ES
Lung Cancer; 2014 May; 84(2):110-5. PubMed ID: 24598368
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
Doebele RC; Pilling AB; Aisner DL; Kutateladze TG; Le AT; Weickhardt AJ; Kondo KL; Linderman DJ; Heasley LE; Franklin WA; Varella-Garcia M; Camidge DR
Clin Cancer Res; 2012 Mar; 18(5):1472-82. PubMed ID: 22235099
[TBL] [Abstract][Full Text] [Related]
25. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
Sasaki T; Okuda K; Zheng W; Butrynski J; Capelletti M; Wang L; Gray NS; Wilner K; Christensen JG; Demetri G; Shapiro GI; Rodig SJ; Eck MJ; Jänne PA
Cancer Res; 2010 Dec; 70(24):10038-43. PubMed ID: 21030459
[TBL] [Abstract][Full Text] [Related]
26. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Kwak EL; Bang YJ; Camidge DR; Shaw AT; Solomon B; Maki RG; Ou SH; Dezube BJ; Jänne PA; Costa DB; Varella-Garcia M; Kim WH; Lynch TJ; Fidias P; Stubbs H; Engelman JA; Sequist LV; Tan W; Gandhi L; Mino-Kenudson M; Wei GC; Shreeve SM; Ratain MJ; Settleman J; Christensen JG; Haber DA; Wilner K; Salgia R; Shapiro GI; Clark JW; Iafrate AJ
N Engl J Med; 2010 Oct; 363(18):1693-703. PubMed ID: 20979469
[TBL] [Abstract][Full Text] [Related]
27. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.
Tanizaki J; Okamoto I; Okabe T; Sakai K; Tanaka K; Hayashi H; Kaneda H; Takezawa K; Kuwata K; Yamaguchi H; Hatashita E; Nishio K; Nakagawa K
Clin Cancer Res; 2012 Nov; 18(22):6219-26. PubMed ID: 22843788
[TBL] [Abstract][Full Text] [Related]
28. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.
Kim S; Kim TM; Kim DW; Go H; Keam B; Lee SH; Ku JL; Chung DH; Heo DS
J Thorac Oncol; 2013 Apr; 8(4):415-22. PubMed ID: 23344087
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition.
Kogita A; Togashi Y; Hayashi H; Sogabe S; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
Int J Oncol; 2014 Oct; 45(4):1430-6. PubMed ID: 25096400
[TBL] [Abstract][Full Text] [Related]
30. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.
Demeure MJ; Aziz M; Rosenberg R; Gurley SD; Bussey KJ; Carpten JD
World J Surg; 2014 Jun; 38(6):1296-305. PubMed ID: 24633422
[TBL] [Abstract][Full Text] [Related]
31. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
32. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
[TBL] [Abstract][Full Text] [Related]
33. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
[TBL] [Abstract][Full Text] [Related]
34. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.
Lin YT; Yu CJ; Yang JC; Shih JY
Clin Lung Cancer; 2016 Sep; 17(5):e77-e94. PubMed ID: 27130468
[TBL] [Abstract][Full Text] [Related]
35. K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.
Mengoli MC; Barbieri F; Bertolini F; Tiseo M; Rossi G
Lung Cancer; 2016 Mar; 93():55-8. PubMed ID: 26898615
[TBL] [Abstract][Full Text] [Related]
36. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
Croegaert K; Kolesar JM
Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
[TBL] [Abstract][Full Text] [Related]
37. Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.
Bayliss R; Choi J; Fennell DA; Fry AM; Richards MW
Cell Mol Life Sci; 2016 Mar; 73(6):1209-24. PubMed ID: 26755435
[TBL] [Abstract][Full Text] [Related]
38. TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.
Amin AD; Li L; Rajan SS; Gokhale V; Groysman MJ; Pongtornpipat P; Tapia EO; Wang M; Schatz JH
Oncotarget; 2016 Apr; 7(17):23715-29. PubMed ID: 27009859
[TBL] [Abstract][Full Text] [Related]
39. In Vitro Drug Sensitivity Tests to Predict Molecular Target Drug Responses in Surgically Resected Lung Cancer.
Miyazaki R; Anayama T; Hirohashi K; Okada H; Kume M; Orihashi K
PLoS One; 2016; 11(4):e0152665. PubMed ID: 27070423
[TBL] [Abstract][Full Text] [Related]
40. The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.
Infarinato NR; Park JH; Krytska K; Ryles HT; Sano R; Szigety KM; Li Y; Zou HY; Lee NV; Smeal T; Lemmon MA; Mossé YP
Cancer Discov; 2016 Jan; 6(1):96-107. PubMed ID: 26554404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]